The schizophrenia psychopharmacology research program at Mount Sinai is dedicated to the advancement of the psychopharmacological treatment of patients with schizophrenia. The goals of this program are:
- To encourage the use of evidence based pharmacological practices by clinicians who treat patients with schizophrenia.
- Participate in multicenter trials of select novel antipsychotic treatments as they become available.
- Systematically evaluate pharmacological augmentation approaches to improve the cognitive, self care, social and occupational functioning of patients with schizophrenia.
- Evaluate approaches to approve outcome in patients treated with clozapine.
Icahn School of Medicine
One Gustave L. Levy Place
New York, NY 10029